Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies

被引：0
|
作者：
Park, Yeon Hee
Cortes, Javier
Modi, Shanu
Hurvitz, Sara A.
Bianchini, Giampaolo
Iwata, Hiroji
Shitara, Kohei
Siena, Salvatore
Goto, Yasushi
Ku, Geoffrey Yuyat
Charles, Powell Andrew
Swain, Sandra M.
Arunachalam, Meena
Janek, Martin
Cheng, Yingkai
Chu, Changan
Verma, Purnima
Mathias, Elton
Karnoub, Maha
Rugo, Hope S.
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[2] Quironsalud Grp, IBCC, Pangaea Oncol, Barcelona, Spain
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Univ Washington, Sch Med, Seattle, WA USA
[5] Fred Hutchinson Canc Ctr, Seattle, WA USA
[6] Univ Vita Salute San Raffaele, Milan, Italy
[7] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[8] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[9] Univ Milan, Milan, Italy
[10] Niguarda Canc Ctr, Milan, Italy
[11] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[12] Tisch Canc Inst, Mt Sinai Hosp, New York, NY USA
[13] Georgetown Univ, Washington, DC USA
[14] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[15] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
12118
引用
收藏
页数：1
相关论文
共 50 条
  • [31] IN VITRO AND IN VIVO EFFICACY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN EPITHELIAL OVARIAN CANCER WITH HER2/NEU OVEREXPRESSION
    Mutlu, Levent
    Manavella, Diego
    Bellone, Stefania
    Santin, Alessandro
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A54 - A54
  • [32] Trastuzumab deruxtecan (T-DXd) sensitivity in various levels of HER2 expressing gastric cancer cells.
    Yu, Seo Young
    Park, Juin
    Kwon, Woo Sun
    Jeong, Inhye
    Kang, Sun Kyoung
    Bae, Hyun Joo
    Kim, Tae Soo
    Chung, Hyun Cheol
    Rha, Sun Young
    CANCER RESEARCH, 2021, 81 (13)
  • [33] A meta-analysis analyzing the efficacy of trastuzumab-deruxtecan (T-DXd) on central nervous system (CNS) disease in patients with metastatic breast cancer (mBC)
    Kumar, Prashanth Ashok
    Sandhu, Michael
    Sravanthi, Metlapalli Venkata
    Desai, Devashish
    Kumar, Vishnu Charan Suresh
    Benjamin, Sam
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Artificial intelligence analysis of advanced breast cancer patients from a phase I trial of trastuzumab deruxtecan (T-DxD): HER2 and histopathology features as predictors of clinical benefit
    Modi, S.
    Glass, B.
    Prakash, A.
    Taylor-Weiner, A.
    Elliott, H.
    Wapinski, I.
    Sugihara, M.
    Saito, K.
    Kerner, J. Kaplan
    Phillips, R.
    Shibutani, T.
    Honda, K.
    Khosla, A.
    Beck, A. H.
    Cogswell, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S355 - S356
  • [35] Rescue Therapy with Trastuzumab Deruxtecan (T-Dxd) in Patients with primary hepatic metastatic Her2 low Breast Cancer with marked Hyperbilirubinemia
    Wolf, M.
    Sili, F.
    Sulejmani, V.
    Schuepferling, A.
    Bomhard, J.
    Huber, M.
    Sigl, S.
    Schnelzer, A.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (06) : E44 - E44
  • [36] Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients
    Wekking, D.
    Porcu, M.
    Pellegrino, B.
    Lai, E.
    Mura, G.
    Denaro, N.
    Saba, L.
    Musolino, A.
    Scartozzi, M.
    Solinas, C.
    ESMO OPEN, 2023, 8 (06)
  • [37] Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+metastatic breast cancer (mBC) from DESTINY-Breast-01,-02, and-03
    Saura, Cristina
    Cortes, Javier
    Modi, Shanu
    Kim, Sung-Bae
    Hamilton, Erika P.
    Hurvitz, Sara A.
    Krop, Ian E.
    Curigliano, Giuseppe
    Iwata, Hiroji
    Im, Seock-Ah
    Herbolsheimer, Pia Maarit
    Karnoub, Maha
    Gambhire, Dhiraj
    Egorov, Anton
    Andre, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] The efficacy and safety of trastuzumab deruxtecan (T-DXd) in HER2-expressing solid tumours: a single-arm meta-analysis
    Kou, Liqiu
    Chen, Xiu
    Xie, Xiaolu
    Wen, Qinglian
    Li, Jun
    Li, Yaling
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (08) : 722 - 729
  • [39] Trastuzumab deruxtecan (T-DXd) in patients with HER2+metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.
    Jerusalem, Guy Heinrich Maria
    Park, Yeon Hee
    Yamashita, Toshinari
    Hurvitz, Sara A.
    Modi, Shanu
    Andre, Fabrice
    Krop, Ian E.
    Gonzalez, Xavier
    Hall, Peter S.
    You, Benoit
    Saura, Cristina
    Kim, Sung-Bae
    Osborne, Cynthia R. C.
    Sagara, Yasuaki
    Tokunaga, Eriko
    Liu, Yali
    Cathcart, Jillian
    Lee, Caleb C.
    Perrin, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies.
    Bando, Hideaki
    Kinoshita, Ichiro
    Modi, Shanu
    Tsurutani, Junji
    Bang, Yung-Jue
    Iwata, Hiroji
    Sato, Yuta
    Nakatani, Shunsuke
    Lee, Caleb C.
    Sugihara, Masahiro
    Okuda, Yasuyuki
    Takahashi, Shunji
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345